Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
Pierre Sié Hematology Laboratory, Academic Hospital of Toulouse, Hospital Rangueil, Toulouse, France Abstract: Idarucizumab is the first targeted antidote of dabigatran, a direct oral anticoagulant used for prevention and treatment of venous thromboembolism and prevention of stroke in atria...
Αποθηκεύτηκε σε:
| Κύριος συγγραφέας: | |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2016-05-01
|
| Σειρά: | Drug Design, Development and Therapy |
| Θέματα: | |
| Διαθέσιμο Online: | https://www.dovepress.com/spotlight-on-idarucizumab-and-its-potential-for-the-reversal-of-antico-peer-reviewed-article-DDDT |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|